LAX.SH
ONESOURCE SPECL PHARMA L·Healthcare Companies·Pharmaceuticals & Biotechnology Companies
Price
1,377.8
+1.52%52W Range
Market Cap
₹15,799.63 Cr
Traded: ₹14.70 Cr (0.09%) 0.0x
Free Float: ₹3,695.53 Cr (0.40% of FF traded)
Volume · 60D trend
1.08 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
RS Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | -- | +131.0% | +232.0% | -- | -2.0% | Stable |
| Profit | -- | +8.0% | +24.0% | -- | -161.0% | Stable |
| Return | -- | -- | -- | +9.0% | -- | -- |
| ROE | -- | -10.0% | -2.0% | -- | -- | Accelerating |
Quarterly Results
Sep 2024
Jun 2024
Mar 2024
Dec 2023
Sep 2023
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 449 | 428 | 290 | 376 | 327 | 426 | 393 | 334 | 292 | 73 | 56 | 34 |
| Expenses | 326 | 336 | 273 | 269 | 239 | 243 | 251 | 257 | 228 | 76 | 67 | 72 |
| Operating Profit | 123 | 92 | 17 | 106 | 88 | 183 | 142 | 77 | 64 | -3 | -10 | -39 |
| Other Income | 0 | 2 | -2 | 3 | 2 | 2 | -94 | -1 | -1 | 3 | -74 | -32 |
| Interest | 31 | 23 | 38 | 34 | 27 | 33 | 46 | 45 | 42 | 20 | 26 | 25 |
| Depreciation | 72 | 72 | 70 | 70 | 68 | 68 | 69 | 68 | 68 | 20 | 20 | 18 |
| Profit Before Tax | 20 | 0 | -93 | 6 | -4 | 83 | -67 | -37 | -47 | -40 | -130 | -114 |
| Tax % | -23.0% | -1630.0% | -5.0% | -83.0% | -96.0% | -19.0% | 4.0% | 12.0% | -88.0% | 0.0% | 0.0% | 0.0% |
| Net Profit | 25 | 5 | -89 | 10 | 0 | 98 | -69 | -42 | -6 | -40 | -130 | -114 |
| Exceptional Items | -- | 0 | -7 | 0 | -3 | -1 | -101 | -6 | -5 | -0 | -75 | -32 |
| EPS (Rs) | 2.2 | 0.4 | -7.7 | 0.9 | -0.0 | 8.6 | -6.0 | -- | -- | -- | -- | -- |
| Sales Growth (YoY) | -- | 0.5% | -26.0% | 12.5% | 12.0% | 482.4% | 598.4% | 891.0% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -- | 47.5% | -22.7% | 14.8% | -23.2% | 8.5% | 17.5% | 14.3% | 299.6% | 30.1% | 66.8% | -- |
| OP Growth (YoY) | 39.8% | -49.7% | -88.0% | 37.7% | 37.5% | 6200.0% | 1520.0% | 297.4% | -- | -- | -- | -- |
| OP Growth (QoQ) | 33.7% | 441.2% | -84.0% | 20.5% | -51.9% | 28.9% | 84.4% | 20.3% | 2233.3% | 70.0% | 74.4% | -- |
| Profit Growth (YoY) | -- | -95.0% | -418.0% | 128.0% | 268.0% | 347.0% | 147.0% | 53.0% | -- | -- | -- | -- |
| EPS Growth (YoY) | -- | -95.3% | -28.6% | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 105.2% | -941.3% | 4700.0% | -100.2% | 243.0% | -- | -- | -- | -- | -- | -- |
| OP Margin | -- | 21.5% | 6.0% | 28.3% | 27.0% | 42.9% | 36.1% | 23.1% | 22.0% | -3.8% | -18.7% | -114.2% |
| Net Margin | -- | 1.1% | -30.6% | 2.8% | -0.1% | 23.1% | -17.5% | -12.6% | -1.9% | -54.9% | -231.6% | -337.4% |
| Material Cost % | -- | 34.2% | 32.5% | 29.6% | 28.4% | 26.0% | 25.9% | 37.1% | 33.8% | 25.6% | 45.6% | 68.8% |
| Employee Cost % | -- | 14.7% | 21.3% | 16.7% | 17.9% | 12.0% | 14.6% | 16.2% | 18.1% | 27.8% | 33.8% | 57.5% |
| P/S | 10.24 | 13.34 | 14.78 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | -- | -- | 1034.01 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 2.71 | 3.25 | 3.55 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Earnings Call to discuss the Unaudited Financial Results of the Company for the quarter ended September 30, 2026
Onesource Specialty Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve OneSource Specialty ....
Addendum to the notice of the 19th AGM scheduled to be held on September 23, 2026
Intimation of the investor presentation
Newspaper advertisement confirming the dispatch of the notice convening the 19th AGM of the Company and Remote e-voting
Business Responsibility and Sustainability Report for the FY 2026
Intimation of the Notice of the 19th AGM (2nd AGM after listing), to be held on September 23, 2026 at 5:00 pm through Video Conferencing or other Audio Visual Means
Annual Report for FY 2025-26
Annual Report for FY 2025-26
Intimation of Investors called scheduled on September 03, 2026 at 10:00 AM.
Newspaper advertisement regarding the 19th Annual General Meeting of the Company
Intimation of Credit Rating issued by India Ratings and Research Private Limited vide press release dated August 17, 2026
Changes in Senior Management Personnel (SMP) of the Company - Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation about publication of newspaper advertisement- Extract of unaudited Standalone and Consolidated financial results for the quarter ended June 30, 2026.
Intimation of Audio Recording of Earnings call pertaining to the Unaudited Financial Results for the quarter ended June 30, 2026
Changes in the Senior Managament Personnel of the Company-Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
OneSource announces strong Q1FY27 results Revenue up 37% YoY and EBITDA up 39% YoY
Intimation of allotment of 2,900 ESOPs of Re.1 each under ONESOURCE ESOP 2021
Outcome of the Board meeting dated July 24, 2026, for the approval of the unaudited financial results (Standalone and Consolidated) for the quarter ended June 30, 2026.
Onesource Specialty Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/07/2026 ,inter alia, to consider and approve Unaudited financial ....
OneSource Specialty Pharma and Formycon AG announce Strategic Manufacturing Partnership for Biosimilars
We refer to the intimation made earlier today by Dr. Reddy''s Laboratories (DRL) regarding delay in commercial supplies of Semaglutide. Refer intimation attached.
Allotment of 24,190 equity shares of Re. 1/- under ONESOURCE ESOP 2021 on July 08, 2026.
We wish to inform that a routine current Good Manufacturing (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the Sterile Product Division facility ....
Intimation of closure of Trading window for declaration of unaudited financial results for the quarter ended June 30, 2026.
In furtherance to the intimation dated May 13, 2026, w.r.t the resignation of SMP, please find enclosed the resignation document.
Intimation of Transcript of Earnings call dated May 13, 2026
We wish to inform that the Government of Karnataka has accorded in-principle approval for the application submitted by the Company for Unit-II expansion project under the Karnataka Industrial ....
Intimation about publication of newspaper advertisement - Extract of Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026
Intimation of the outcome of the Board meeting dated May 13, 2026 for approval of the Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026
Intimation of Audio Recording of Earnings call pertaining to the Audited Financial Results for the quarter and financial year ended March 31, 2026
Update on Composite Scheme of Arrangement and Amalgamation (Merger by Absorption) amongst Steriscience Specialities Private Limited, Brooks Steriscience Limited, Steriscience Pte. Limited, ....
Appointment of BSR & Co.LLP Chartered Accountants as the Statutory Auditors of the Company.
Intimation regarding the earnings presentation for Q4 FY 2026
Onesource announces FY 2026 results with strong Q4 performance; reaffirms FY28 guidance.
Allotment of 3,150 Equity Shares of Re.1/- each under ONESOURCE ESOP SCHEME 2021.
Intimation reagrding resignation of Senior Management Personnel effective from May 13, 2026
Onesource Specialty Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2026 ,inter alia, to consider and approve the Audited Standalone ....
Intimation regarding earnings call to be held on May 13, 2026
OneSource supports Second Generic Semaglutide approval in Canada- Enables commercialisation for the first two entrants in the World''s second largest Semaglutide market.
OneSource''s Partner Dr. Reddy''s Laboratories receives Health Canada approval for Generic Semaglutide Injection.
Intimation regarding receipt of EU GMP Certificate for Sterile Product Division
Press release: Orbicular''s Partner secures tentative U.S. ANDA approval for a generic version of Ozempic (Semaglutide Injection), supported by OneSource as CDMO Partner.
Intimation of the renewal of EU -GMP Certification for OneSource: Flagship Unit II Facility located in Bengaluru.
Intimation of ESG Rating received from NSE Sustainability Ratings and Analytics Limited
Allotment of 21,450 equity shares of Re. 1 each/- under ONESOURCE ESOP 2021 on April 09, 2026
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
Intimation of Closing of Trading Window for the declaration of Financial Results for the quarter and year ended March 31, 2026.
Update on Composite Scheme of Arrangement and Amalgamation( Merger by Absorption) amongst Steriscience Specialties Private Limited, Brooks Steriscience Limited, Steriscience Pte. Ltd, Strides ....
Re-affirmation and withdrawal of credit ratings from CareEdge Ratings.
Annual Reports
12025
Credit Ratings
5Concalls
6Jan 2026
31 Jan 2026Nov 2025
30 Nov 2025Sep 2025
30 Sept 2025Aug 2025
31 Aug 2025May 2025
31 May 2025Feb 2025
28 Feb 2025Held by ETFs
16 ETFs hold ONESOURCE · sorted by weight
Held by Mutual Funds
51 schemes hold ONESOURCE · sorted by weight